If your teen struggles with focus, the medication question rarely stays simple. You balance what the prescriber recommends against what the research shows, and what most people around you assume is the only path forward. On June 26, 2026, Axsome Therapeutics announced the first patient had been dosed in FOCUS-3, a Phase 3 clinical trial testing solriamfetol as a non-stimulant ADHD treatment in 468 adolescents ages 12 to 17. The drug pipeline news is real and worth knowing. What most coverage skips is three decades of research showing that attention is a trainable cognitive skill, and that training it changes the brain in ways no six-week medication trial is designed to track.
A new Phase 3 ADHD drug trial launched for teens on June 26, 2026. Here are the questions parents are actually asking.
Common questions
Is solriamfetol approved for teens with ADHD?
Should I try attention training instead of ADHD medication for my teen?
What does non-stimulant mean for ADHD treatment?
How do I know if a treatment is building my teen’s attention or only managing symptoms?
Pharma launched a new non-stimulant ADHD trial for teens this week. Three decades of research show attention is trainable. Coverage owes parents both sides of the story.
The Trial and What Is Being Tested
FOCUS-3 (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled multicenter trial. Approximately 468 adolescents with ADHD ages 12 to 17 will be enrolled and randomized 1:1:1 to receive one of two doses of solriamfetol or placebo over six weeks. The primary measure is change from baseline in the ADHD Rating Scale (ADHD-RS-5) total score at week 6.
Solriamfetol works as a dopamine and norepinephrine reuptake inhibitor, plus TAAR1 agonist and 5-HT1A agonist, a non-stimulant mechanism that distinguishes it from amphetamine-based first-line treatments. The CDC reported in 2024 that approximately 7 million U.S. children are diagnosed with ADHD, and research in the American Journal of Psychiatry found that approximately two-thirds or more of children with ADHD continue to experience symptoms into adulthood (Sibley et al., 2022). The estimated annual societal cost of adult ADHD in the United States exceeds $120 billion (Schein et al., J Manag Care Spec Pharm, 2022).
Currently approved non-stimulant options for adolescents with ADHD are limited to atomoxetine, extended-release guanfacine, clonidine, and viloxazine. Solriamfetol would add a distinct mechanism to that short list if FOCUS-3 succeeds and FDA review follows.
The Frame Coverage Keeps Missing
Every new ADHD drug trial gets reported as progress for children who struggle, and that framing is not wrong. It is incomplete. While the pharmaceutical industry funds six-week symptom trials, a parallel body of research has been building a different case: attention is a cognitive skill that responds to training, not only to chemistry.
A 2024 randomized controlled trial of 62 adolescents with ADHD tested a structured executive working memory training program and found clear evidence of target engagement with improvements on task-specific outcomes (ScienceDirect, 2024). Meta-analytic reviews confirm that adaptive cognitive training leverages neuroplasticity to strengthen the brain regions most affected in ADHD, including the prefrontal cortex. This is the same plasticity principle that brain-imaging research at Yale (Shaywitz) and Stanford (Temple) documented in children who struggled with reading: with the right kind of practice, the brain physically rewires. The same mechanism governs how attention networks develop.
The distinction that coverage consistently skips is the difference between symptom management and skill development. Solriamfetol, if it completes trials and reaches approval, would provide a pharmacological scaffold during the treatment window. Attention training, by contrast, aims to strengthen the underlying neural networks so the scaffold becomes less necessary over time. Both approaches have evidence behind them. What most parents are not given is a clear explanation of which goal any intervention is pursuing, or what the research shows about building attention skills alongside medication.
Key takeaways
- New Trial Launches: Axsome Therapeutics dosed the first patient in FOCUS-3 on June 26, 2026, a non-stimulant ADHD trial enrolling 468 adolescents ages 12 to 17 over six weeks.
- Attention Is Trainable: A 2024 RCT in adolescents with ADHD found measurable brain engagement from executive function training; neuroplasticity research confirms that attention networks strengthen with structured practice.
- Two Different Goals: Symptom management and skill building are not the same thing. Parents deserve clear answers on which one any given intervention is pursuing.
The Questions Worth Putting to Your Child’s Doctor
If your child’s provider raises a new ADHD medication, a few questions belong on the table. First: is this medication intended to help your child function while building skills, or is it the primary plan? Second: what does the research show about what happens to attention when the medication is tapered or stopped? A treatment that builds underlying capacity answers that differently than one that manages symptoms in the moment.
The research on attention development points consistently toward factors parents do control: structured attention practice with progressive difficulty, regular physical movement (which increases dopamine and strengthens prefrontal cortex function), quality sleep, and intentional management of high-stimulation screen time. None of those require waiting for a trial to complete or a drug to be approved, and none carry the uncertainty about adolescent safety data that any Phase 3 trial, by definition, has not yet resolved.
The pharmaceutical-first framing for teen ADHD is not wrong. Medications help many adolescents function well enough to learn, and a non-stimulant option with a novel mechanism is genuinely worth watching. The slip happens when managing symptoms well enough to get through class gets treated as the same thing as building the attention skills that hold up when the medication is not there. Parents who understand both goals are better equipped to ask the right questions and push for both.
Every drug trial announcement that reaches a parent carries an implicit message: this is where the answer lives. The true villain in teen ADHD coverage is not any drug or company. It is the framing that hands parents a pipeline update and sends them home without the training side of the story. Your teen’s attention is not a neurochemical state waiting for the right pill. It is a system of neural networks that grows stronger with the right kind of challenge. If you are ready to explore what building attention looks like in practice, the All Access program is where to start.
See what All Access gives your child
Explore Focus Foundations
Is your child struggling in school?
Get your free personalized learning roadmap
You describe what you see at home. We turn it into a plan you start this week.
- Answer 5 short questionnaires about what you already notice, 30–45 minutes at your own kitchen table
- Your child sits no test and gets no score: nothing to schedule, nothing for them to dread
- You do the answering, the AI does the writing, and a person reviews it before it reaches you
- Access all 40+ courses instantly: reading, math, focus, processing and more, with new ones added regularly
Why we use AI, plainly: it writes from a knowledge base our team maintains and audits. We work through it line by line and pull anything the evidence stops supporting. The roadmap you get on Tuesday reflects what we corrected on Monday, and a human still reads it before you do.
Your school district must evaluate your child free of charge if you ask in writing, whatever your income and whatever the outcome (US, 34 CFR 300.111 and 300.301(b)). That route takes time and answers a different question than you do. This one starts today, from what you already know.
Your answers stay yours. We do not sell your personal information, and we do not hand identifiable assessment data to outside AI companies to train their models.
A screener is a starting point, not a diagnosis. If your child might need formal accommodations (an IEP or 504 plan), or you suspect a vision, hearing or medical cause, pursue a professional evaluation too. That is the only route to those supports.
References
- GlobeNewswire — Axsome Therapeutics, FOCUS-3 Phase 3 Trial Initiation (June 26, 2026)
- Centers for Disease Control and Prevention — Data and Statistics on ADHD (2024)
- Sibley MH et al. — Variable Patterns of Remission From ADHD in the Multimodal Treatment Study of ADHD. Am J Psychiatry. 2022;179(2):142–151.
- Schein J et al. — Economic burden of ADHD among adults in the U.S. J Manag Care Spec Pharm. 2022;28(2):168–179.
- ScienceDirect — Executive working memory training RCT in adolescents with ADHD (2024)
